According to ICER’s QALY calculations, Zolgensma would be worth $310,000 to $900,000 for type 1 SMA patients, or $710,000 to $1.5 million using the LYG assessment.

Funding medical research is about more than just numbers. It's real people,” says Ryan Manriquez, president of the UC ...

Hoffmann-La Roche AG) , seeking permanent injunction to prevent the introduction of a generic drug for Spinal Muscular Atrophy (SMA) jeopardises public interest by limiting access to affordable ...

The results add to the growing body of evidence within the OAV101 IT development program, which has evaluated a broad population of over 170 patients with SMA, spanning a total of over 6.4 years ...

One of my favorite things about springtime is the return of the local bird life, especially the songbirds. While certain ...

Chugai Pharma’s Evrysdi tablets 5mg receives Japanese approval to treat spinal muscular atrophy: Saturday, March 29, 2025, 11:00 Hrs [IST] Chugai Pharmaceutical Co., Ltd. announ ...

SMA has not revealed any specific measures yet, but job cuts are likely. Discussions with the company's co-determination body will take place in the coming weeks. SMA said these steps will help it ...

SMA patients who can sit see improvements in motor function over 12 months of treatment with DMTs, particularly in fine motor skills.